Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
— Marks the first novel psilocybin analog to enter clinical development —— Patient recruitment to commence immediately — — Pharmacokinetic and safety data readout expected in Q4 2022 — TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that it has received a … [Read more…]